Predictors of Discontinuation of Subdermal Levonorgestrel Implants (Jadelle) at the Lagos University Teaching Hospital, Lagos, Nigeria: An Analytic Cohort Study

Ephraim Ohazurike, Joseph A. Olamijulo, Latifat Ibisomi, Gbenga Olorunfemi, Ayodeji A. Oluwole


Uptake and continuation of long acting reversible contraceptives (LARC) such as subdermal levonorgestrel implants are pivotal to the achievement of some sustainable development goals (SDG). We evaluated Jadelle uptake and factors affecting its discontinuation in the first three years of initiation at the Family Planning Clinic of the College of Medicine, University of Lagos (CMUL), Nigeria. A retrospective cohort study was conducted among 517 consecutive new Jadelle acceptors, at the family planning clinic of CMUL, between 1 October 2007 and 30 September 2010, who were followed up till 30 September 2011. Survival life table analysis, Kaplan-Meier plots and multivariable Cox proportional hazard regression were conducted to evaluate factors affecting time to Jadelle discontinuation. Stata version 13 statistical software (StataCorp USA) was used for analysis. The mean age of Jadelle acceptors was 32.9 (S.D: ±5.4) years and uptake rate of Jadelle was 61.8%. The overall discontinuation rate was 19 per 100 women-years while the 1-year, 2-year and 3-year Jadelle discontinuation rates were 7.1%; 27.0% and 58.1% respectively. Increased age, (P=0.047) and previous contraceptive use (P <0.001) were independent predictors of Jadelle discontinuation. Menstrual irregularity (51.4%) and intention to get pregnant (40.3%) were the commonest reasons for discontinuation. The failure rate was low at 0.27 per 100 women-years. This study showed that Jadelle had a high uptake rate complimented by a low failure rate; and is quite suitable for postpartum childbirth spacing as well as ongoing long term contraception. (Afr J Reprod Health 2020; 24[2]: 48-63).

Full Text:



Essien EJ, Monjok E, Smesny A and Ekabua EJ.

Contraceptive practices in Nigeria: Literature review and recommendation for future policy decisions. Open Access J Contracept. 2010;1:1–14.

Barden-O’Fallon J, Speizer IS, Cálix J and Rodriguez F.

Contraceptive Discontinuation among Honduran Women Who Use Reversible Methods. Stud Fam Plann. 2011;42(1):11–20.

Elias B and Hailemariam T. Implants Contraceptive

Utilization and Factors Associated among Married Women in the Reproductive Age Group (18-49 years) in Southern Ethiopia. J Women s Heal Care [Internet]. 2015;4(7). Available from:

National Population Commission, ICF. Nigeria

Demographic and Health Survey 2013.

Alabi OO, Olorunfemi G, and Onile TG. The trend in

maternal mortality in an upgraded tertiary facility in North Central Nigeria. Niger J Med. 2012; 21: 282–9.

WHO. Trends in Mternal Mortality: 1990-2013.

Estimates by WHO,UNICEF, UNFPA, The World Bank and the United Nations Population Division. World Health Organization[Internet]. 2014;56. Available from:

Olamijulo JA, Olorunfemi G, Olaleye O, Ogedengbe OK

and Giwa-Osagie OF. Trends in maternal mortality at the Lagos University Teaching Hospital, Lagos, Nigeria. Nig Q J Hosp Med [Internet]. 2012;22: 72–9.

Bankole A, Oye-Adeniran BA, Singh S, Adewole IF,

Wulf D, and Sedgh G, . Unwanted Pregnancy And Induced Abortion In Nigeria: Causes And Consequences [Internet]. Vol. 32, International Family Planning Perspectives. 2006.

Starbird E, Norton M and Marcus R. Investing in Family

Planning : Key to Achieving the Sustainable Development Goals. Glob Heal Sci Pract. 2016;4(2):191–210.

Jacobstein R and Polis CB. Progestin-only contraception:

Injectables and implants. Best Pract Res Clin Obstet Gynaecol [Internet]. Elsevier Ltd; 2014;28(6):795–806.

American Congress of Obstetricians and Gynecologists.

Long-Acting Reversible Contraception :Implants and Intrauterine Devices [Internet]. Vol. No. 121, ACOG Practice Bulletins. 2011. Report No.: 121.

Okafor II. Uptake of Long-Acting Reversible

Contraceptive Methods in Enugu State University Teaching Hospital. Divers Equal Heal Care. 2016;13:216–20.

Aisien AO. Contraception with levonorgestrel subdermal

implants (Norplant) in Benin-City, Nigeria: a 12-year review. Afr J Reprod Health 2007;11:90–7.

Teunissen AM, Grimm B, Roumen FJME. Continuation

rates of the subdermal contraceptive Implanon® and associated influencing factors. Eur J Contracept Reprod Heal Care. 2014;19:15–21.

Raine TR, Foster-rosales A, Upadhyay UD, Boyer CB,

Brown BA and Sokoloff A, . One-Year Contraceptive Continuation and Pregnancy in Adolescent Girls and Women Initiating Hormonal Contraceptives. Obs Gynecol 2011;117:363–71.

Maina SW, Osanjo GO, Ndwigah SN and Opanga SA.

Determinants of Discontinuation of Contraceptive Methods among Women at Kenyatta National Hospital , Kenya. African J Pharmacol Ther. 2016; 5:28–34.

Igwe NM, Nnamdi EB and Jude AJ. A 5-Year Clinical

Evaluation of Subdermal Implants Among Abakaliki Acceptors. J Basic Clin Reprod Sci | 2016;2:1–5.

Kalmuss D, Davidson AR, Cushman LF, Heartwell S

and Rulin M. Determinants of early implant discontinuation among low-income women. Fam Plann Perspect. 1996; 28(6): 256–60.

Mutihir JT and Nyango DD. Indications for removal of

etonogestrel implant within two years of use in Jos, Nigeria. East Afr Med J. 2010; 87(11): 2010.

Enyindah CE and Kasso T. Jadelle subdermal implants .

Preliminary experience in a teaching hospital in the Niger Delta Region of Nigeria . Niger J Med 2011; 20(2) :270–4.

Madugu NH, Abdul MA, Bawa U and Kolawole B.

Uptake of Hormonal Implants Contraceptive in Zaria , Northern Nigeria. Open J Obstet Gynecol [Internet]. 2015;5:268–73. Available from:

Ramstrom KC, Barón AE, Crane LA and Shlay JC.

Predictors of contraceptive discontinuation in a sexually transmitted disease clinic population. Perspect Sex Reprod Health. 34(3):146–522

Curtis S, Evens E and Sambisa W. Contraceptive

discontinuation and unintended pregnancy: An imperfect relationship. Int Perspect Sex Reprod Health. 2011;37(2):58–66.

Adegbola O and Ogedengbe O. The acceptance rate of

intrauterine contraceptive device (IUCD) amongst family planning clinic users in Lagos University Teaching Hospital (LUTH). Nig Q J Hosp Med 2008; 18: 175–80.

Aisien AO and Enosolease ME. Safety, efficacy and

acceptability of Implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital. Niger J Clin Pract. 2010;13:331–5.

Abasiattai AM, Utuk NM and Inyang-etoh EC.

Subdermal Contraceptive Implants: Profile of Acceptors in a Tertiary Hospital in Southern Nigeria. Int J Gynecol Obstet Neonatal Care. 2014; 1: 9–13.

Ozumba B, Chukudebelu W and Snow R. Norplant as a

contraceptive device in Enugu, Eastern Nigeria. Adv Contracept. 1998;14(2):109–19.

Ezegwui HU, Ikeako LC, Ishiekwene CI and Oguanua

TC. The discontinuation rate and reasons for discontinuation of implanon at the family planning clinic of University of Nigeria Teaching Hospital (UNTH. Niger J Med. 2011;4:448–50. 29.

Muhammad Z and Maimuna DG. Contraceptive trend in

a tertiary facility in North Western Nigeria : A 10 ‑ year review. Niger J Basic Clin Sci. 2014; 11(2) :99–103.

Bahamondes L. Subdermal implantable contraceptives

versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy. Geneva: WHO; 1998.

Olamijulo JA and Olorunfemi G. Knowledge and

practice of contraception among pregnant women attending the antenatal clinic in Lagos University Teaching Hospital. Niger J Med 2012;21:387–93.


  • There are currently no refbacks.